

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

FEB 27 2006

Sheet

1

of

5

COMPLETE IF KNOWN**Application Number**

10/556,805

Filing Date

November 14, 2005

First Named Inventor**Tesfaye Biftu, et al.**

Group Art Unit

1624

Examiner Name

Coleman

Attorney Docket Number

21404P

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
/B.C./	8	PCT	WO 03/082817 A2		MERCK & CO., INC.	10/09/2003
/B.C./	9	PCT	WO 03/000180 A2		MERCK & CO., INC.	01/03/2003
/B.C./	10	PCT	WO 03/000181 A2		MERCK & CO., INC.	01/03/2003
	11	PCT	WO 03/000181 A3		MERCK & CO., INC.	01/03/2003
/B.C./	12	PCT	WO 02/076450 A1		MERCK & CO., INC.	10/03/2002
/B.C./	13	PCT	WO 2004/007468 A1		MERCK & CO., INC.	01/22/2004
/B.C./	14	PCT	WO 2004/032836 A2		MERCK & CO., INC.	04/22/2004
/B.C./	15	PCT	WO 2004/050022 A2		MERCK & CO., INC.	06/17/2004
/B.C./	16	PCT	WO 2004/058266 A1		MERCK & CO., INC.	07/15/2004
/B.C./	17	PCT	WO 2004/064778 A2		MERCK & CO., INC.	08/05/2004

Examiner
Signature

/Brenda Coleman/

Date
Considered

09/14/2008

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

(use as many sheets as necessary)

Sheet

2

of

5

Application Number

10/556,805

Filing Date

November 14, 2005

First Named Inventor

Teshaye Biftu, et al.

Group Art Unit

1624

Examiner Name

Coleman

Attorney Docket Number

21404P

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
/B.C./	18	PCT	WO 2004/069162 A2		MERCK & CO., INC.	08/19/2004
/B.C./	19	PCT	WO 02/02560 A2		NOVO NORDISK A/S	01/10/2002
/B.C./	20	PCT	WO 01/96295 A2		NOVARTIS AG	12/20/2001
	21	PCT	WO 01/96295 A2		NOVARTIS AG	12/20/2001
/B.C./	22	PCT	WO 01/34594 A1		Guilford Pharmaceuticals, Inc.	05/17/2001
/B.C./	23	PCT	WO 00/34241		NOVARTIS AG	06/15/2000
/B.C./	24	PCT	WO 98/19998 A2		NOVARTIS AG	05/14/1998
	25	PCT	WO 98/19998 A2		NOVARTIS AG	05/14/1998
/B.C./	26	PCT	WO 97/40832		Hansknoll-Institut Fur Naturstoff-Forschung E.V.	11/06/1997
	27	PCT	WO 03/008188 A3		MERCK & CO., INC.	01/03/2003

✻ ✻

Examiner
Signature

/Brenda Coleman/

Date
Considered

09/14/2008

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

er for Patents, P. O. Box 1450, Alex
 ** Structures only

STATEMENT BY APPLICANT

COMPLETE IF KNOWN

Application Number	10/556,805
Filing Date	November 14, 2005
First Named Inventor	Tesfaye Biftu, et al
Group Art Unit	1624
Examiner Name	Coleman

Sheet	3	of	5	Attorney Docket Number	21404P
-------	---	----	---	------------------------	--------

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
	28	PCT	WO 02/02560	A3	NOVO NORDISK	01/10/2002
/B.C./	29	PCT	WO 01/42262		AKZO NOBEL N.V.	06/14/2001
/B.C./	30	PCT	WO 2004/043940		MERCK & CO., INC.	05/27/2004
	31	PCT	WO 2004/007468		MERCK & CO., INC.	01/23/2004
/B.C./	32	PCT	WO 2004/110436		MERCK & CO., INC.	12/23/2004
/B.C./	33	PCT	WO 2004/112701	A2	MERCK & CO., INC.	12/29/2004
	34	PCT	WO 2004/112701	A3	MERCK & CO., INC.	12/29/2004
/B.C./	35	PCT	WO 2005/011581	A2	MERCK & CO., INC.	02/10/2005
/B.C./	36	PCT	WO 2005/044195	A2	MERCK & CO., INC.	05/19/2005
/B.C./	37	PCT	WO 2005/002530 03/02530	A2	SMITHKLINE BEECHAM CORP.	01/09/2003

09/14/2008

SEND TO: Commissioner for Patents, P. O. Box. 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
/B.C./	38	PCT	WO 2005/056003	A1	GRAFFINITY PHARMACEUTICALS AG	06/23/2005
/B.C./	39	PCT	WO 2005/056013	A1	GRAFFINITY PHARMACEUTICALS AG	06/23/2005
/B.C./	40	PCT	WO 2005/108382	A1	MERCK & CO., INC.	11/17/2005
/B.C./	41	PCT	WO 2005/116029	A1	MERCK & CO., INC.	12/08/2005
/B.C./	42	PCT	WO 2005/123685	A1	ASTRAZENECA AB	12/29/2005

Examiner Signature	/Brenda Coleman/	Date Considered	09/14/2008
-----------------------	------------------	--------------------	------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	10/556,805
				Filing Date	November 14, 2005
				First Named Inventor	Tesfaye Biftu, et al.
				Group Art Unit	1624
				Examiner Name	Coleman
Sheet	5	of	5	Attorney Docket Number	21404P

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/B.C./	43	J. J. Holst, "Treatment of Type 2 Diabetes Mellitus with Agonists of the GLP-1 Receptor or DPP-IV Inhibitors", Expert Opin. Emerg. Drugs, Vol. 9(1) pp. 155-166(2004).
/B.C./	44	C. F. Deacon, et al., "Inhibitors of dipeptidyl peptidase IV: A Novel Approach for the Prevention and Treatment of Type 2 Diabetes?", Expert Opin. Investig. Drugs, Vol. 13(9) pp. 1091-1102(2004).
/B.C./	45	K. Augustyns et al., " Dipeptidyl Peptidase IV Inhibitors as New Therapeutic Agents for the Treatment of Type 2 Diabetes", Expert Opin. Ther. Patents, Vol. 13(4), pp. 499-510(2003).
/B.C./	46	Novartis AG: WO0034241, "Novel N-substituted-2-Cyanopyrrolidines as Potent Inhibitors of Dipeptidyl Peptidase IV in the Treatment of Non-Insulin-Dependent Diabetes Mellitus", Exp. Opin. Ther. Patents, Vol. 10(12), pp. 1937-1942 (2000).
	47	O. J. Grucker, "Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes", Exp. Opin. Invest. Drugs, Vol.12, pp. 87-100 (2004).
/B.C./	48	T. P. Vahl & D. A. D'Alessio, "Gut peptides in the treatment of diabetes mellitus" Exp. Opin. Invest. Drugs, Vol. 13, pp. 177-188 (2004).
/B.C./	49	L. B. Knudsen, "Glucagon-like peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes", J. Med. Chem, Vol. 47, pp. 4128-4134 (2004).
/B.C./	50	A. E. Weber, "Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes", J. Med. Chem, Vol. 47, pp. 4135-4141 (2004).
/B.C./	51	J. J. Holst and C. F. Deacon, "Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus", Curr. Opin Pharmacology, Vol. 4, pp. 589-596 (2004).
/B.C./	52	C. F. Deacon, "Perspectives in Diabetes - Therapeutic Strategies Based on Glucagon-Like Peptide 1", Diabetes, Vol. 53, pp. 2181-2189 (2004).
/B.C./	53	K. Augustyns, et al., "Inhibitors of proline-specific dipeptidyl peptidase: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes", Expert Opin. Ther. Patents, Vol. 15(10), pp. 1387-1407 (2005).
/B.C./	54	Hans-Ulrich Demuth, et al., " Type 2 diabetes - Therapy with dipetidyl peptidase IV inhibitors", Biochimica et Biophysica Acta, Vol. 1751, pp., 33-44 (2005).

Examiner Signature	/Brenda Coleman/	Date Considered	09/14/2008
--------------------	------------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005